US5364943A
(en)
*
|
1991-11-27 |
1994-11-15 |
Pfizer Inc. |
Preparation of substituted piperidines
|
DK0589924T3
(da)
*
|
1991-06-20 |
1996-09-30 |
Pfizer |
Fluoralkoxybenzylaminoderivater af nitrogenholdige heterocyclusser
|
EP0916346A3
(en)
|
1991-09-20 |
2000-12-06 |
Glaxo Group Limited |
NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
|
WO1993023380A1
(en)
*
|
1992-05-18 |
1993-11-25 |
Pfizer Inc. |
Bridged aza-bicyclic derivatives as substance p antagonists
|
WO1994003445A1
(en)
*
|
1992-08-04 |
1994-02-17 |
Pfizer Inc. |
3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
|
DE69331103T2
(de)
*
|
1992-08-19 |
2002-03-14 |
Pfizer Inc., New York |
Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
|
WO1994013663A1
(en)
*
|
1992-12-10 |
1994-06-23 |
Pfizer Inc. |
Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists
|
US6369074B1
(en)
*
|
1992-12-10 |
2002-04-09 |
Pfizer Inc. |
Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
|
US5340826A
(en)
*
|
1993-02-04 |
1994-08-23 |
Pfizer Inc. |
Pharmaceutical agents for treatment of urinary incontinence
|
GB9305718D0
(en)
*
|
1993-03-19 |
1993-05-05 |
Glaxo Group Ltd |
Medicaments
|
US5294744A
(en)
*
|
1993-04-20 |
1994-03-15 |
Pfizer Inc. |
Formylation process for aromatic aldehydes
|
DK0700384T3
(da)
|
1993-05-28 |
1997-12-08 |
Pfizer |
fremgangsmåde til fremstilling og opløsning af 2-phenyl-3-aminopiperidin
|
US5393762A
(en)
*
|
1993-06-04 |
1995-02-28 |
Pfizer Inc. |
Pharmaceutical agents for treatment of emesis
|
EP0653208A3
(en)
*
|
1993-11-17 |
1995-10-11 |
Pfizer |
Substance P antagonists for the treatment or prevention of sunburn.
|
EP0659409A3
(en)
*
|
1993-11-23 |
1995-08-09 |
Pfizer |
Substance P antagonists for the inhibition of angiogenesis.
|
EP0655246A1
(en)
*
|
1993-11-30 |
1995-05-31 |
Pfizer Inc. |
Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
|
FR2728166A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Composition topique contenant un antagoniste de substance p
|
FR2728169A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
|
FR2728165A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
|
EP0826684B1
(en)
*
|
1995-03-27 |
2001-11-21 |
Hisamitsu Pharmaceutical Co., Inc. |
Piperidine derivatives
|
TW340842B
(en)
*
|
1995-08-24 |
1998-09-21 |
Pfizer |
Substituted benzylaminopiperidine compounds
|
FR2741262B1
(fr)
|
1995-11-20 |
1999-03-05 |
Oreal |
Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
|
ATE223896T1
(de)
*
|
1995-12-21 |
2002-09-15 |
Pfizer |
3-((5-substituierte benzyl)amino)-2- phenylpiperidine als substance-p-antagonisten
|
US6329396B1
(en)
|
1996-06-10 |
2001-12-11 |
Pfizer Inc. |
Substituted benzylaminopiperidine compounds
|
CA2287487A1
(en)
*
|
1997-04-24 |
1998-10-29 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating eating disorders
|
GB9716457D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
AU737019B2
(en)
*
|
1997-08-04 |
2001-08-09 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating aggressive behaviour disorders
|
AU738047B2
(en)
*
|
1997-08-04 |
2001-09-06 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating mania
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9816897D0
(en)
*
|
1998-08-04 |
1998-09-30 |
Merck Sharp & Dohme |
Therapeutic use
|
RS49964B
(sr)
|
1999-05-17 |
2008-09-29 |
Pfizer Products Inc., |
Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
|
DE60007599T2
(de)
*
|
1999-10-18 |
2004-11-11 |
Pfizer Products Inc., Groton |
Verfahren zur Herstellung von zyklischen Piperidinylaminomethyl-trifluoromethyl-etherderivaten
|
US7163949B1
(en)
|
1999-11-03 |
2007-01-16 |
Amr Technology, Inc. |
4-phenyl substituted tetrahydroisoquinolines and use thereof
|
BR0015320A
(pt)
|
1999-11-03 |
2002-07-09 |
Albany Molecular Res Inc |
Composto, composição, métodos de tratamento de um distúrbio que e criado pela, ou é dependente da, disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, para inibir a captação da serotonina, da dopamina e de norepinefrina sinápticas em um paciente em necessidade destes, e, kit
|
IL142810A0
(en)
*
|
2000-05-03 |
2002-03-10 |
Pfizer Prod Inc |
Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
|
NZ523456A
(en)
|
2000-07-11 |
2004-11-26 |
Albany Molecular Res Inc |
Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
|
US7067535B2
(en)
*
|
2000-09-26 |
2006-06-27 |
Tanabe Seiyaku Co., Ltd. |
5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis
|
AU2001292320A1
(en)
*
|
2000-10-02 |
2002-04-15 |
Tanabe Seiyaku Co., Ltd. |
Benzylamine compound, process for producing the same, and intermediate therefor
|
US6911544B2
(en)
|
2002-10-23 |
2005-06-28 |
Pfizer Inc. |
Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
|
BRPI0511183A
(pt)
*
|
2004-05-21 |
2007-12-04 |
Pfizer Prod Inc |
metabólitos de (+)-(2s, 3s)-3-(2-metóxi-5-trifluorometoxibenzilamino)-2-fenil- piperidina
|
MX2007000428A
(es)
|
2004-07-15 |
2008-03-05 |
Amr Technology Inc |
Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina.
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
JP5406525B2
(ja)
*
|
2005-07-04 |
2014-02-05 |
ツァナン・サイテック・カンパニー・リミテッド |
ルテニウム錯体配位子、ルテニウム錯体、固定化ルテニウム錯体触媒及びその調製方法と用途
|
WO2007011820A2
(en)
|
2005-07-15 |
2007-01-25 |
Amr Technology, Inc. |
Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
WO2007015588A1
(en)
*
|
2005-08-04 |
2007-02-08 |
Takeda Pharmaceutical Company Limited |
Piperidine derivative as tachykinin receptor antagonist
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
BRPI0806245B1
(pt)
|
2007-01-10 |
2022-01-25 |
Msd Italia S.R.L. |
Compostos de fórmula i e seus usos
|
KR20090112722A
(ko)
|
2007-01-24 |
2009-10-28 |
글락소 그룹 리미티드 |
3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 r(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 nk1을 포함하는 제약 조성물
|
CA2682727C
(en)
|
2007-04-02 |
2016-03-22 |
Banyu Pharmaceutical Co., Ltd. |
Indoledione derivative
|
JP5501227B2
(ja)
|
2007-06-27 |
2014-05-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体
|
CN102014631A
(zh)
|
2008-03-03 |
2011-04-13 |
泰格尔医药科技公司 |
酪氨酸激酶抑制剂
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
AR071997A1
(es)
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
KR20120023072A
(ko)
|
2009-05-12 |
2012-03-12 |
브리스톨-마이어스 스큅 컴퍼니 |
(S)-7-(〔1,2,4〕트리아졸〔1,5-a〕피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도
|
DK2429296T3
(en)
|
2009-05-12 |
2018-03-12 |
Albany Molecular Res Inc |
7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
|
WO2010132437A1
(en)
|
2009-05-12 |
2010-11-18 |
Albany Molecular Research, Inc. |
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
|
CN104945382B
(zh)
|
2009-10-14 |
2020-02-07 |
默沙东公司 |
提高p53活性的取代的哌啶和其用途
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
JP6043285B2
(ja)
|
2010-08-02 |
2016-12-14 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害
|
WO2012024170A2
(en)
|
2010-08-17 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US20140046059A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Process for the preparation of morpholino sulfonyl indole derivatives
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
CA2892361A1
(en)
|
2012-11-28 |
2014-06-05 |
Merck Sharp & Dohme Corp. |
Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
|
BR112015013611A2
(pt)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
composto, e, composição farmacêutica
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
CN103204768A
(zh)
*
|
2013-03-12 |
2013-07-17 |
西北大学 |
一种对羟基苯甲醛的合成方法
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
WO2018071283A1
(en)
|
2016-10-12 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Kdm5 inhibitors
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US11098059B2
(en)
|
2017-11-08 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
WO2020019247A1
(en)
*
|
2018-07-26 |
2020-01-30 |
Xw Laboratories, Inc. |
Compounds as neurokinin-1 receptor antagonists and uses thereof
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|